OR7E108P

Across TCGA pan-cancer cohorts, OR7E108P RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated OR7E108P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR7E108P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR7E108P expression acts as an unfavorable survival marker, although some lineages such as LUAD and PRAD show a favorable association.

LIHC, SKCM, and PCPG are the cancer types where OR7E108P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.264	0.736	<.001	84	view →
SKCM	OS	Tertile	II,III,IV	0.099	0.379	.001	36	view →
PCPG	DFS	Tertile	All	0.298	0.779	<.001	36	view →
COAD	OS	Tertile	All	0.710	0.886	.005	36	view →
UCS	OS	Tertile	IV	0.253	0.691	.022	18	view →
READ	DFS	Tertile	IV	0.141	0.671	<.001	18	view →
THCA	OS	Tertile	II,III,IV	0.704	0.856	.048	9	view →
LGG	DFS	Tertile	All	0.280	0.470	.031	6	view →
LUAD	OS	Tertile	All	0.769	0.624	.032	5	view →
PRAD	OS	Tertile	All	1.000	0.828	.019	4	view →
STAD	OS	Median	IV	0.537	0.219	.048	3	view →
LUSC	DFS	Median	II,III,IV	0.669	0.553	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

OR7E108P–LIHC (OS)

Open the LIHC breakdown →